Unusual first presentation of a metabolic disorder
- PMID: 30904888
- PMCID: PMC6510225
- DOI: 10.1136/bcr-2018-226716
Unusual first presentation of a metabolic disorder
Abstract
An 8-month-old boy presented to hospital with a fever, irritability and 'back arching'. On examination, he demonstrated profound opisthotonic posturing and had tonsillitis. He had a full septic screen and was treated with broad spectrum antibiotics. Blood tests showed a transaminitis, raised alpha fetoprotein and deranged clotting. The clotting abnormalities and raised alpha fetoprotein persisted post discharge and an abdominal ultrasound showed steatosis, splenomegaly and bilateral increased renal cortical reflectivity. A full metabolic screen revealed type 1 tyrosinaemia. The opisthotonic posturing, a major part of this child's presentation, has not been reported as a presenting feature of tyrosinaemia. It was part of a 'neurological crisis' caused by tyrosinaemia and exacerbated by the intercurrent infection. These are known to occur in tyrosinaemia but not commonly as the first presentation. This represents an unusual presentation of a metabolic condition which, without intervention, can lead to severe hepatic, renal and neurodevelopmental complications.
Keywords: congenital disorders; metabolic disorders; paediatrics.
© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome.Nutrients. 2020 Dec 31;13(1):134. doi: 10.3390/nu13010134. Nutrients. 2020. PMID: 33396520 Free PMC article.
-
Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S223-5. doi: 10.1007/s10545-008-0807-z. Epub 2008 May 20. J Inherit Metab Dis. 2008. PMID: 18500574
-
Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).J Inherit Metab Dis. 1996;19(2):234-8. doi: 10.1007/BF01799438. J Inherit Metab Dis. 1996. PMID: 8739974 No abstract available.
-
Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.Expert Opin Pharmacother. 2008 May;9(7):1229-36. doi: 10.1517/14656566.9.7.1229. Expert Opin Pharmacother. 2008. PMID: 18422479 Review.
-
Hereditary tyrosinaemia type I: from basics to progress in treatment.Ann Med. 2000 Nov;32(8):530-8. doi: 10.3109/07853890008998832. Ann Med. 2000. PMID: 11127930 Review.
Cited by
-
Hereditary Tyrosinemia Compounded With Hyperinsulinemic Hypoglycemia: Challenging Diagnosis of a Rare Case.Cureus. 2020 Nov 18;12(11):e11541. doi: 10.7759/cureus.11541. Cureus. 2020. PMID: 33365210 Free PMC article.
References
-
- Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001;10:1741–52. - PubMed
-
- Holme E. Blau, et al. eds 2003. 141–53.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical